Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Selected for European Kindergarten Lighting to Support Children’s Learning and Eye Health
20.10.2020 05:30:00 EEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that LED Luks , a European manufacturer of LED luminaires, has adopted Seoul Semiconductor’s SunLike Series natural spectrum LEDs for private kindergarten facilities’ lighting in Slovenia to support children’s learning and eye health.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005912/en/
(Fig.1) SunLike natural spectrums for Morning – Noon – Evening Colors (Graphic: Business Wire)
In cooperation with LED Luks, Seoul Semiconductor has developed the optimal SunLike Series LED designs based on the natural spectrum light source for the lighting. With SunLike Series natural spectrum LED technology, LED Luks has used lighting brand “ARUN” to support children’s concentration and relaxation with an optimal smart solution for remotely and automatically adjusting the color temperature and dimming representing the light from noon to evening.
The light in noon color mode helps children’s brains more alert and also improve academic performance. The light in the evening color mode makes them more creative and feel relaxed. It also provides high sleep quality by promoting melatonin, thus encouraging the production of growth hormone and boosting memory and immunity. Human body produces growth hormone up to 80% of the daily GH production during sleep. Deep, non-REM sleep helps human brain to wash away waste and to regenerate cells, supporting immunity.
Earth is estimated to be 4.5 billion years old. With natural sunlight, under which all animals on the earth have evolved over 3.9 billion years, plants over 450 million years, insects over 360 million years, and humans over 7 million years. Based on circle of day – month – year, human’s DNA has evolved and a circadian rhythm is internal process that regulates the sleep-wake cycle based on 24-hour body clock that natural sunlight affects.
SunLike Series LEDs are the world’s first technology and have been recognized as an innovative technology that produces light that closely matches the spectrum of natural sunlight by a total of ten global lighting awards held in Korea, Europe, China, and the US over the past three years. Based on the results of a comprehensive sleep study conducted by Professor Christian Cajochen and his colleagues at the University of Basel in Switzerland, LED light sources with the same measured intensity and correlated color temperature (CCT), but different spectral output, can have different effects on human behavior and physiology. The study, published in the Journal of Lighting & Research Technology on March 24, 2019, found “evidence that daylight [natural spectrum] LED solution has beneficial effects on visual comfort, daytime alertness, mood, and sleep intensity in healthy volunteers.” According to the results of a study done by the Bio-Information Laboratory of Seoul National University Hospital in July of 2018, SunLike Series natural spectrum LEDs have been shown to reduce eye discomfort and improve sleep patterns. In addition, Seoul Semiconductor has been conducting experiments on protection from myopia and students’ learning and concentration with influential university research teams in Europe and the US for three years, and is expected to announce the study results in the second half of 2020.
“Young people who spend long hours of indoor study and the lack of exposure to daylight particularly need to use a better quality of LED lighting which closely matches natural spectrum of sunlight,” said Carlo Romiti, Europe sales Vice President of Seoul Semiconductor. “We believe that Seoul Semiconductor’s SunLike Series natural spectrum LEDs will be necessary technology for human-centric lighting to support human health, well-being and better performance of daily life, children’s healthy growth as well with three beneficial effects in contrast to conventional LEDs: Better Study, Better Eye Health and Better Immunity.”
Introduced in June 2017, the SunLike Series natural spectrum LEDs are an advanced light source that combine the latest optical and compound semiconductor technology of Seoul Semiconductor with Toshiba Materials’ TRI-R® technology. TRI-R, supported by Toshiba Materials, finds in the definition “The light closest to the sun for human well-being” its original concept. The sunlight spectrum is developed by the same company and can be reproduced by a white LED light source technology. TRI-R is a registered trademark by the Toshiba Materials Co., LTD.
About Seoul Semiconductor
Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 10,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phone, computer displays, and other applications, as well as the UV area. The company’s world’s first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all direction light emitting technology, filament LED; a natural spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201019005912/en/
Contact information
Seoul Semiconductor Co., Ltd.
Jeonghee Kim
Tel: +82-70-4391-8311
Email: jeonghee.kim@seoulsemicon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 17:25:00 EEST | Press release
Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
